These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 31062738)
1. Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia. Lei M; Liu L; Wang Z; Wu D Indian J Cancer; 2019; 56(2):167-172. PubMed ID: 31062738 [TBL] [Abstract][Full Text] [Related]
2. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia. Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434 [TBL] [Abstract][Full Text] [Related]
3. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia. Qu Q; Liu L; Zhang Y; Li X; Wu D Leuk Res; 2015 Dec; 39(12):1353-9. PubMed ID: 26432074 [TBL] [Abstract][Full Text] [Related]
4. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study. Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551 [TBL] [Abstract][Full Text] [Related]
5. The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy. Chen Y; Yang T; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Hu J Medicine (Baltimore); 2016 Jul; 95(30):e4182. PubMed ID: 27472687 [TBL] [Abstract][Full Text] [Related]
6. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis. Minakata D; Fujiwara S; Ito S; Mashima K; Umino K; Nakano H; Kawasaki Y; Sugimoto M; Yamasaki R; Yamamoto C; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727 [TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC]. Liu J; Jia JS; Gong LZ; Lu SY; Zhu HH; Huang XJ; Jiang H Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):734-738. PubMed ID: 30369183 [No Abstract] [Full Text] [Related]
8. Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy. Zhu HH; Jiang H; Jiang B; Lu J; Jiang Q; Bao L; Zhang XH; Qin YZ; Huang XJ Leuk Lymphoma; 2013 Nov; 54(11):2452-7. PubMed ID: 23432721 [TBL] [Abstract][Full Text] [Related]
9. Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia. Liu L; Zhang Y; Jin Z; Zhang X; Zhao G; Si Y; Lin G; Ma A; Sun Y; Wang L; Wu D Int J Hematol; 2014; 99(5):603-8. PubMed ID: 24623261 [TBL] [Abstract][Full Text] [Related]
10. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome. Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772 [TBL] [Abstract][Full Text] [Related]
11. Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia. Jin J; Chen J; Suo S; Qian W; Meng H; Mai W; Tong H; Huang J; Yu W; Wei J; Lou Y Leuk Lymphoma; 2015 Jun; 56(6):1691-7. PubMed ID: 25257348 [TBL] [Abstract][Full Text] [Related]
12. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia. Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269 [TBL] [Abstract][Full Text] [Related]
14. Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia. Huang J; Hong M; Zhu Y; Zhao H; Zhang X; Wu Y; Lian Y; Zhao X; Li J; Qian S Leuk Lymphoma; 2018 Nov; 59(11):2570-2579. PubMed ID: 29616840 [TBL] [Abstract][Full Text] [Related]
15. Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21). Wang Y; Li W; Chen S; Qiu H; Sun A; Wu D Leuk Res; 2011 May; 35(5):604-7. PubMed ID: 21130493 [TBL] [Abstract][Full Text] [Related]
16. [Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia]. Zhu BG; Qian SX; Hong M; Lu H; Wu HX; Zhang SJ; Qiu HX; Xu W; Li JY Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):760-4. PubMed ID: 19549403 [TBL] [Abstract][Full Text] [Related]
17. [Efficacy of induction chemotherapy for patients with high-risk myelodysplastic syndrome (MDS) or MDS-transformed acute myeloid leukemia with CHG regimen and its comparison with regimen GAG and HA]. Su JY; Chang CK; Zhang X; Zhou LY; Song LQ; Xu L; Wu LY; He Q; Li X Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):459-63. PubMed ID: 19379588 [TBL] [Abstract][Full Text] [Related]
18. [Therapeutic effect of priming induction regimen of CAG for newly diagnosed acute myeloid leukemia in elderly patients]. Chen YJ; Zhang LQ; Li XL; Zhao XL; Wu DS; Shu YG; Chen FP Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 33(3):245-51. PubMed ID: 18382060 [TBL] [Abstract][Full Text] [Related]
19. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828 [TBL] [Abstract][Full Text] [Related]
20. Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis. Huang R; He H; Xu X; Lin X; Dong Y; Wang X; Jiang F; Huang P; Mo S; Huang Z; Wang Y; Tao H; Zheng Y; Wu M; Yang C; Zheng Z; Zhao Y; Zhang Y; Li Y Cancer; 2024 Jul; 130(14):2472-2481. PubMed ID: 38470375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]